<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">World J Gastrointest Pathophysiol</journal-id>
<journal-id journal-id-type="publisher-id">WJGP</journal-id>
<journal-title-group>
<journal-title>World Journal of Gastrointestinal Pathophysiology</journal-title>
</journal-title-group>
<issn pub-type="ppub">2150-5330</issn>
<issn pub-type="epub">2150-5330</issn>
<publisher>
<publisher-name>Baishideng Publishing Group Inc</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26600975</article-id>
<article-id pub-id-type="pmc">4644881</article-id>
<article-id pub-id-type="other">jWJGP.v6.i4.pg169</article-id>
<article-id pub-id-type="doi">10.4291/wjgp.v6.i4.169</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Gastrointestinal dysbiosis and the use of fecal microbial transplantation in <italic>Clostridium difficile</italic> infection</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Schenck</surname>
<given-names>L Patrick</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Beck</surname>
<given-names>Paul L</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>MacDonald</surname>
<given-names>Justin A</given-names>
</name>
</contrib>
<aff>L Patrick Schenck, Gastrointestinal Research Group at the Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary AB T2N 4Z6, Canada</aff>
<aff>Paul L Beck, Gastrointestinal Research Group at the Snyder Institute for Chronic Diseases and Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary AB T2N 4Z6, Canada</aff>
<aff>Justin A MacDonald, Gastrointestinal Research Group at the Snyder Institute for Chronic Diseases and Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, T2N 4Z6, Canada</aff>
</contrib-group>
<author-notes>
<fn>
<p>Author contributions: Schenck LP, Beck PL and MacDonald JA performed the literature review and wrote the paper.</p>
<p>Correspondence to: Justin A MacDonald, Professor, Gastrointestinal Research Group at the Snyder Institute for Chronic Diseases and Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary AB T2N 4Z6, Canada. <email>jmacdo@ucalgary.ca</email></p>
<p>Telephone: +1-403-2108433</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>15</day>
<month>11</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>11</month>
<year>2015</year>
</pub-date>
<volume>6</volume>
<issue>4</issue>
<fpage>169</fpage>
<lpage>180</lpage>
<history>
<date date-type="received">
<day>25</day>
<month>6</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>28</day>
<month>8</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>10</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>Â©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement>
<copyright-year>2015</copyright-year>
</permissions>
<abstract>
<p>The impact of antibiotics on the human gut microbiota is a significant concern. Antibiotic-associated diarrhea has been on the rise for the past few decades with the increasing usage of antibiotics. <italic>Clostridium difficile</italic> infections (CDI) have become one of the most prominent types of infectious diarrheal disease, with dramatically increased incidence in both the hospital and community setting worldwide. Studies show that variability in the innate host response may in part impact upon CDI severity in patients. That being said, CDI is a disease that shows the most prominent links to alterations to the gut microbiota, in both cause and treatment. With recurrence rates still relatively high, it is important to explore alternative therapies to CDI. Fecal microbiota transplantation (FMT) and other types of bacteriotherapy have become exciting avenues of treatment for CDI. Recent clinical trials have generated excitement for the use of FMT as a therapeutic option for CDI; however, the exact components of the human gut microbiota needed for protection against CDI have remained elusive. Additional investigations on the effects of antibiotics on the human gut microbiota and subsequent CDI will help reduce the socioeconomic burden of CDI and potentially lead to new therapeutic modalities.</p>
</abstract>
<kwd-group>
<kwd>Human gut microbiota</kwd>
<kwd>Antibiotic-associated diarrhea</kwd>
<kwd>Fecal microbial transplant</kwd>
<kwd>Bacteriotherapy</kwd>
<kwd>Dysbiosis</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>